Home    Contact    Sitemap    Search    
  Print page    
  
News
2010.05.30   Photocure announces US approval of Cysview(TM) for detection of bladder cancer  
2010.05.28   Photocure announces results from phase II study in acne with Visonac™  
2010.05.26   Feil i regelverket for Innsatsstyrt Finansiering  
2010.05.11   Photocure wins patent case against the US Patent and Trademark Office  
2010.04.28   1st quarter 2010 results  
2010.04.27   Åse Aulie Michelet foreslås som nytt styremedlem i Photocure  
2010.04.26   Presentation of the 1st quarter 2010 report  
2010.04.21   Expert panel recommends the use of Hexvix®-cystoscopy  
2010.04.07   Notice of annual general meeting  
2010.03.29   Annual Report 2009  
2010.03.18   Allotted Share Options  
2010.03.08   Shares purchased by employees and notification of trade  
2010.02.19   Presentation 4th Quarter 2009  
2010.02.19   Results 4th quarter and full year 2009  
2010.02.16   Presentation of the annual report 2009  
2010.01.13   Hexvix® receives reimbursement approval in Germany  
2010.01.06   Inclusion completed in phase II study with Visonac™ for acne  
2010.01.06   Financial calendar 2010  
2009.12.31   Photocure received positive response from FDA on the New Drug Application (NDA) for Hexvix® for detection of bladder cancer  
2009.12.18   FDA Advisory Committee voted favourably to Hexvix® application in USA  
2009.11.26   Photocure granted patent in Europe and Russia for Visonac™ in the treatment of acne  
2009.11.25   Extraordinary General Meeting  
2009.11.23   Shares purchased by employees  
2009.11.20   FDA has posted an Advisory Committee meeting with Photocure to discuss Hexvix® NDA  
2009.11.03   Notice of extraordinary general meeting  

 
  Photocure ASA, Hoffsveien 48, NO-0377 Oslo, Norway. Telephone: +47 22 06 22 10 Fax: +47 22 06 22 18